SABCS 2025 News: Updated EMBER-3 Efficacy Results for …
4 days ago · Updated survival outcomes from the EMBER-3 trial reinforced the clinical benefit of imlunestrant as monotherapy and in combination with abemaciclib as oral, chemotherapy-free …
ELEVATE Trial: Elacestrant Combos Boost PFS in ER+/HER2- Breast Cancer …
5 days ago · Key Takeaways Elacestrant combined with everolimus or abemaciclib showed significant PFS benefits in ER-positive, HER2-negative metastatic breast cancer patients. The …
Nivolumab plus low-dose ipilimumab in hypermutated HER2-negative …
May 13, 2025 · In the phase II NIMBUS trial, patients with human epidermal growth factor receptor 2 (HER2)-negative metastatic breast cancer (MBC) and high tumor mutational burden …
Updated data for Lilly's Inluriyo™ (imlunestrant) reinforce efficacy ...
5 days ago · as monotherapy for the treatment of adult patients with HR-positive, HER2-negative advanced or metastatic breast cancer with disease progression following endocrine therapy …
Giredestrant-Based Combo Boosts PFS Across Subgroups in …
4 days ago · Giredestrant plus everolimus reduced progression risk in ER+, HER2-negative breast cancer, outperforming standard endocrine therapy plus everolimus, regardless of …
Neratinib Plus Capecitabine for the Treatment of Her2-Negative ...
This phase II trial tests how well neratinib in combination with capecitabine works in treating patients with HER2-negative breast cancer that has spread from where it first started (primary …
1 in 4 metastatic breast cancer patients treated with
Dec 9, 2025 · The post-hoc exploratory analysis of the MONALEESA-2, -3 and -7 trials in first-line HR+/HER2- MBC aimed to identify clinical characteristics and biomarkers of patients who …
1 in 4 metastatic breast cancer patients treated with Novartis …
Basel, December 9, 2025 – Novartis today announced results showing that one in four patients with hormone receptor-positive, human epidermal growth factor receptor 2-negative …
ADCs in Breast Cancer: Shaping the Future of HER2 ... - Pharmacy …
5 days ago · TROP-2-targeting ADCs, SG and Dato-DXd, are approved for metastatic breast cancer, showing efficacy in HR+, HER2-negative, and triple-negative subtypes. Optimal …
Novel Drug Combination Shows Promise for Advanced HER2-Negative Breast …
Feb 14, 2024 · A novel three-drug combination achieved notable responses in patients with advanced HER2-negative breast cancer, according to new research directed by investigators …